Results 61 to 70 of about 11,045,572 (313)

The Impact of the COVID‐19 Pandemic on Childhood Cancer Survival: A Population‐Based Assessment of Survival Patterns Between 2015 and 2023 in Germany

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Numerous international studies have reported declines in new cancer diagnoses, delayed diagnoses and disruptions in cancer treatment following the implementation of COVID‐19 pandemic public health measures, raising concerns that these effects may ultimately contribute to increased cancer mortality.
Friederike Erdmann   +8 more
wiley   +1 more source

Combined Cell Therapy in the Treatment of Neurological Disorders

open access: yes, 2020
Cell therapy of neurological diseases is gaining momentum. Various types of stem/progenitor cells and their derivatives have shown positive therapeutic results in animal models of neurological disorders and in clinical trials.
Leonid V. Gubsky   +7 more
core   +1 more source

Exosomes are natural carriers of exogenous siRNA to human cells in vitro [PDF]

open access: yes, 2013
© 2013 Shtam et al. Background: Exosomes are nano-sized vesicles of endocytic origin that are involved in cell-to-cell communication including shuttle RNA, mainly mRNA and microRNA.
Varfolomeeva, EY   +11 more
core   +1 more source

Enhancing the efficacy of stem cell therapy with glycosaminoglycans [PDF]

open access: yes, 2020
Human mesenchymal stem cell (hMSC) therapy offers significant potential for osteochondral regeneration. Such applications require their ex vivo expansion in media frequently supplemented with fibroblast growth factor 2 (FGF2). Particular heparan sulfate (
Smith, Raymond A. A.   +14 more
core   +1 more source

Comparative analysis and process optimization for manufacturing CAR-T using the PiggyBac system derived from cryopreserved versus fresh PBMCs

open access: yesScientific Reports
Chimeric antigen receptor T (CAR-T) therapy holds promise for cancer treatment but faces challenges with using fresh patient cells, including manufacturing failures and logistical hurdles.
Zenghui Xu   +6 more
doaj   +1 more source

Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies

open access: yesOncoImmunology
CAR-based cell therapies have shown clinical success in treating various cancers, with CAR T cell therapies entering the clinical route and CAR NK cell therapies being evaluated in early-stage clinical trials.
Katharina Schindler-Wnek   +5 more
doaj   +1 more source

Characterization of human induced pluripotent stems cells: Current approaches, challenges, and future solutions

open access: yesBiotechnology Reports, 2023
Human induced pluripotent stem cells (iPSC) have demonstrated massive potentials for use in regenerative and personalized medicine due to their ability to expand in culture and differentiate into specialized cells with therapeutic benefits.
Sahana Suresh Babu   +8 more
doaj   +1 more source

Referral Patterns and Diagnostic Timeliness in Pediatric Cancer: A Hospital‐Based Study in Indonesia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Timely diagnosis and treatment are critical for improving survival among children with cancer. In low‐ and middle‐income countries (LMICs), delays are common and may be influenced by fragmented referral pathways and diagnostic limitations.
Nur Melani Sari   +5 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

open access: yes, 2019
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease.
Saiko Kurosawa   +3 more
core   +1 more source

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy